Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) was downgraded by research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday. They currently have a $7.00 price objective on the stock. Roth Capital’s target price would suggest a potential upside of 11.64% from the stock’s previous close.

A number of other research firms also recently weighed in on ZYNE. Cantor Fitzgerald restated a “buy” rating and set a $28.00 target price on shares of Zynerba Pharmaceuticals in a research report on Tuesday, May 9th. Canaccord Genuity set a $35.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, May 13th. Maxim Group set a $32.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, June 26th. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, BidaskClub raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $17.44.

Shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE) traded down 6.00% on Tuesday, reaching $6.27. The company had a trading volume of 1,678,805 shares. Zynerba Pharmaceuticals has a one year low of $6.18 and a one year high of $25.95. The firm’s market cap is $83.12 million. The company has a 50-day moving average price of $17.54 and a 200-day moving average price of $19.50. Zynerba Pharmaceuticals also saw unusually large options trading on Monday. Stock traders acquired 7,953 put options on the company. This represents an increase of approximately 726% compared to the average daily volume of 963 put options.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, August 1st. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by $0.04. On average, analysts expect that Zynerba Pharmaceuticals will post ($2.46) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/roth-capital-downgrades-zynerba-pharmaceuticals-inc-zyne-to-hold.html.

In related news, Chairman Armando Anido acquired 5,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was acquired at an average cost of $19.70 per share, with a total value of $98,500.00. Following the completion of the purchase, the chairman now directly owns 336,012 shares in the company, valued at $6,619,436.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James E. Fickenscher acquired 5,200 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The shares were bought at an average cost of $19.82 per share, with a total value of $103,064.00. Following the completion of the purchase, the chief financial officer now owns 12,200 shares of the company’s stock, valued at $241,804. The disclosure for this purchase can be found here. 10.02% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. FNY Managed Accounts LLC acquired a new position in Zynerba Pharmaceuticals during the first quarter worth about $180,000. SG Americas Securities LLC acquired a new position in Zynerba Pharmaceuticals during the first quarter worth about $188,000. Rhumbline Advisers acquired a new position in Zynerba Pharmaceuticals during the second quarter worth about $232,000. Bank of New York Mellon Corp boosted its position in Zynerba Pharmaceuticals by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 12,165 shares of the company’s stock worth $245,000 after buying an additional 635 shares during the last quarter. Finally, Segantii Capital Management Ltd acquired a new position in Zynerba Pharmaceuticals during the first quarter worth about $291,000. 31.08% of the stock is owned by hedge funds and other institutional investors.

About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.